Skip to main content
Equibles
RGEN logo

RGEN · Repligen Corp

Track RGEN — free

Use RGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$192.23 -2.34 (-1.20%) At close · Sep 30
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$10.70B
Shares
56.44M
Volume · Sep 30 730.44K Avg daily vol (3M) 1.09M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$192.23 Open$193.09 Day$190.97–195.61 52W close$102.87–194.57 Avg vol 30d1.1M Short int6.7M · 11.9% float · 7.1d Short vol80% Last earningsJul 28, 2026 DataJan 2020–Sep 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 24, 2026 Est · unconfirmed · in 3 wks
Latest filing: 10-Q
filed Jul 29, 2026
Q2 2026 earnings call transcript
call held Jul 28, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$785.10M
Trailing 12 months
Net income (TTM)
$41.54M
Trailing 12 months
Revenue growth YoY
+11.9%
Year over year
Operating margin
8.2%
Trailing 12 months
P / E (TTM)
262.9
Trailing earnings · reciprocal yield 0.4%
FCF yield
1.0%
TTM · current market cap
Return on invested capital
2.8%
Trailing 12 months
Net cash
$259.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.2%
Year over year · more shares
Price change (1Y)
+56.8%
Trailing year
Short interest
11.9%
Latest settlement · 7.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +34%
above
Price vs 50-day avg +14%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 97%
near high
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +60%
trailing
YTD return +17%
this year
Relative strength +48%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $168 › 200d $143 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +98 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.89% of float · ▲ +1.5% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
486 holders — near 3-yr high, broad support
Squeeze score 76
high risk · 0–100
Fundamentals
Excellent
Revenue growth +35%
Y/Y
EPS growth +287%
Y/Y
Free cash flow $93.9M
Buyback $25.0M
authorized
Balance sheet $23.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 45%
annualized · 1-yr
Max drawdown −40%
past year
ATR 3.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 7
Latest guidance · from the 8-K filed Jul 28, 2026
Total Reported Revenue · FY 2026 Initiated $813M – $835M
prior FY $738.26M midpoint +11.6% Y/Y
Reported Growth · FY 2026 Initiated 10% – 13%
Organic Growth · FY 2026 Non-GAAP Initiated 10.5% – 13.5%
Gross Margin · FY 2026 Non-GAAP Initiated 53.7% – 54.2%
Other Income (Expense) · FY 2026 Non-GAAP Initiated $19M
Income from Operations · FY 2026 Non-GAAP Initiated $128M – $134M
Operating Margin · FY 2026 Non-GAAP Initiated 15.7% – 16%
Adjusted EBITDA Margin · FY 2026 Non-GAAP Initiated 20.6% – 21%
Net Income · FY 2026 Non-GAAP Initiated $115.5M – $118.5M
Tax Rate on Pre-Tax Income · FY 2026 Non-GAAP Initiated 22%
Earnings Per Share - Diluted · FY 2026 Non-GAAP Initiated $2.03 – $2.09
Guided vs delivered · last 7 settled
Total Reported Revenue FY 2024
guided $620M – $635M
$634.44M In line
Earnings Per Share - Diluted FY 2024
guided $0.17 – $0.24
$-0.46 Miss −324.4%
Total Reported Revenue FY 2023
guided $635M – $645M
$632.36M Miss −1.2%
Earnings Per Share - Diluted FY 2023
guided $1.26 – $1.32
$0.63 Miss −51.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+34% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
97% Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $168 › 200d $143 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +98 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.89% of float · ▲ +1.5% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
486 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $103 Now $192 · 97% Range high $195
vs 200-day avg +34% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RGEN
Repligen Corp
this stock
$10.70B +17.3% +35.1% — 11.9%
ISRG
Intuitive Surgical Inc
 $143.14B -28.2% +20.5% 46.5 2.3%
BDX
Becton Dickinson & Co
 $49.57B — +8.2% — 4.2%
MDLN
Medline Inc.
 $45.62B -17.4% +11.5% — 3.1%
RMD
Resmed Inc
 $32.02B -8.2% +13.4% 21.3 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
486
% held
118.4%
Net QoQ
+814.5K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
571
View
Short & Settlement
Short Interest Rising
Shares short
6.7M
Days to cover
7.1d
Change
+99.8K sh
View
Short Volume
Short vol %
80%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
321
Value
$52.9K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
45.2%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Lisa McClain
Amount
$1.0K–$15.0K
Traded
Oct 31, 2025
View
Financials
Financials
Revenue (FY)
$141.2M
Net income (FY)
$48.9M
EPS diluted
$0.86
View
Buybacks
Authorized
$25.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 15, 2026
This year
15
View
Proposed Sales
Value
$2.5M
Shares
12.9K
Filed
Sep 24, 2026
View
Earnings & Events
Earnings Calls
Last call
Sep 9, 2026
View
Investor Relations
Latest news
Repligen Corporation to Present a…
Published
Aug 26, 2026
View

Performance

5D 20D 120D MTD YTD
RGEN +4.2% +13.1% +60.5% +6.2% +17.3%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY +4.8% +13.0% +48.3% +6.8% +5.5%

Capital returns

Buyback program · as of Dec 31, 2023
Authorized
$25.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 730272 CUSIP 759916109 13F (30d) 12 filings 12 filers Visit website Investor relations